Our Publications

See all of Dr. Hayek's publications on PubMed

Recent Publication Highlights


Soluble Urokinase Receptor (SuPAR) in COVID-19–Related AKI

Journal of the American Society of Nephrology

"They found suPAR levels to be strongly associated with incident AKI, independent of such clinical characteristics as kidney function and inflammatory biomarkers, and predictive of the need for dialysis. SuPAR may be a key component of the pathophysiology of AKI in COVID-19.."

In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study

British Medical Journal

"48 of the 400 patients (12.0%) who received cardiopulmonary resuscitation survived to hospital discharge, and only 7.0% (28/400) survived to hospital discharge with normal or mildly impaired neurological status. Survival to hospital discharge differed by age, with 21.2% (11/52) of patients younger than 45 years surviving compared with 2.9% (1/34) of those aged 80 or older. "




Clinical and Research Tools for the Study of Cardiovascular Effects of Cancer Therapy

Journal of Cardiovascular Translational Research

"Since the vast array of cancer therapies have varying mechanisms of cardiotoxicity, a multimodality approach involving imaging, genomic, blood-based biomarkers, tissue, and organ level analyses is needed to refine cardiovascular risk stratification among cancer patients. "


Soluble Urokinase Receptor and Acute Kidney Injury

New England Journal of Medicine

"This study showed that suPAR was associated with subsequent acute kidney injury in several cohorts. Concurrently, we obtained experimental evidence that suPAR may be directly involved in the pathogenesis of acute kidney injury by sensitizing kidney proximal tubules to injury through modulation of cellular bioenergetics and increased oxidative stress. Inhibiting suPAR with the use of a monoclonal antibody attenuated the effect of iohexol on kidney function in mice overexpressing suPAR and abrogated bioenergetic changes in HK-2 cells exposed to suPAR."